Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 515-520, August 2008

Outcomes of Volume-Overloaded Cardiovascular Patients Treated With Ultrafiltration

  • Brian E. Jaski, MD

      Affiliations

    • San Diego Cardiac Center, Sharp Memorial Hospital, San Diego, California
    • Corresponding Author InformationReprint requests: Brian E. Jaski, MD, San Diego Cardiac Center, 3131 Berger Avenue, San Diego, CA 92123.
  • ,
  • Andrew Romeo, BS

      Affiliations

    • Sharp Memorial Hospital, San Diego, California
  • ,
  • Bryan Ortiz

      Affiliations

    • Sharp Memorial Hospital, San Diego, California
  • ,
  • Peter M. Hoagland, MD

      Affiliations

    • San Diego Cardiac Center, Sharp Memorial Hospital, San Diego, California
  • ,
  • Maureen Stone, RN

      Affiliations

    • Sharp Memorial Hospital, San Diego, California
  • ,
  • Dale Glaser, PhD

      Affiliations

    • Sharp Memorial Hospital, San Diego, California
  • ,
  • Lorie Thomas, MSN

      Affiliations

    • Sharp Memorial Hospital, San Diego, California
  • ,
  • Cynthia Walsh, MSN

      Affiliations

    • Sharp Memorial Hospital, San Diego, California
  • ,
  • Sidney C. Smith Jr., MD

      Affiliations

    • University of North Carolina, Chapel Hill, North Carolina

Received 27 July 2007; received in revised form 1 February 2008; accepted 5 February 2008. published online 21 May 2008.

Abstract 

Background

Ultrafiltration (UF) can rapidly and predictably remove extracellular and intravascular fluid volume. To date, assessment of UF in patients with cardiovascular disease has been confined to short- and medium-term studies in patients with a principal diagnosis of acute heart failure.

Methods

In-hospital and long-term outcomes were reviewed from consecutive patients with cardiovascular disorders and recognized pulmonary and systemic volume overload treated with a simplified UF system with the capability for peripheral venovenous access. Trained abstractors reviewed both paper and electronic medical records. Patients with a principal diagnosis of heart failure versus other primary hospital discharge diagnoses were identified according to International Classification of Diseases, 9th Revision standards by independent coders.

Results

For a period of 43 months, 100 patients (76 male/24 female, 65 ± 14.0 years of age, systolic dysfunction 64%) were treated with UF during 130 hospitalizations. Baseline systolic blood pressure was 119 ± 23 mm Hg. Before UF, 53% were receiving intravenous vasoactive therapy. By using UF, 7.1 ± 3.9 L of ultrafiltrate were removed during 2.0 ± 1.2 treatments per hospitalization. Baseline creatinine was 1.8 ± 0.8 and 1.9 ± 1.2 (not significant) at discharge. Of the 15 in-hospital deaths, 14 occurred during the initial hospitalization. Left ventricular dysfunction was related to 13 (87%) of the 15 deaths; no deaths were related to UF use. In hospitalizations with a principal diagnosis of heart failure (n = 79), in-hospital mortality was 7.6% compared with an ADHERE risk tree estimated mortality of 7.5%. Multivariate logistic regression identified a trend for decreased systolic blood pressure to predict patient initial hospitalization mortality (P = .06). Kaplan-Meier survivals for all patients were 71% at 1 year and 67% at 2 years. Cox regression found decreased systolic blood pressure as a predictor of long-term mortality (P = .025). Total volume of ultrafiltrate removed, ejection fraction, history of coronary artery disease, creatinine clearance, gender, age, and principal diagnosis of heart failure were not significantly associated with long-term mortality.

Conclusion

This series extends the spectrum of patients previously reported to be treated with UF. Despite marked volume overload, UF-treated patients with a principal diagnosis of heart failure had inpatient outcomes similar to the ADHERE registry. UF should be considered for a broad range of patients who present with volume overload.

Key Words: Heart failure, edema, pulmonary congestion, ultrafiltration

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The study was supported in part by the Rosa Azus Cardiovascular Fund of the Sharp Healthcare Foundation, San Diego, California.

PII: S1071-9164(08)00064-X

doi:10.1016/j.cardfail.2008.02.003

Journal of Cardiac Failure
Volume 14, Issue 6 , Pages 515-520, August 2008